Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL478732 | 1.00 | SCN9A (0.53) | SCN9AITGB3ITGA2BACECTSS | |
| SCHEMBL5717580 | 1.00 | SCN9A (0.53) | SCN9AITGB3ITGA2BACECTSS | |
| Hydrochloric Acid SCHEMBL28584085 | 0.99 | SCN9A (0.52) | SCN9AITGB3ITGA2BACECTSS | |
| SCHEMBL23324594 | 0.89 | SCN9A (0.50) | SCN9AITGB3ITGA2BACECTSS | |
| SCHEMBL25888951 | 0.89 | SCN9A (0.50) | SCN9AITGB3ITGA2BACECTSS | |
| SCHEMBL6161903 | 0.88 | SCN9A (0.54) | SCN9ACTSSCTSKCTSLCTSB | |
| SCHEMBL6161893 | 0.88 | SCN9A (0.54) | SCN9ACTSSCTSKCTSLCTSB | |
| SCHEMBL756368 | 0.87 | FOLH1 (0.47) | SCN9ACTSSCTSKFOLH1ITGA4 | |
| SCHEMBL18731295 | 0.87 | FOLH1 (0.47) | SCN9ACTSSCTSKFOLH1ITGA4 | |
| SCHEMBL6162648 | 0.86 | SCN9A (0.51) | SCN9AITGB3ITGA2BACECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-03-06 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11952352-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4054719-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| US-5756832-A | REACTING AN ALDHYDE WITH AN ORTHOFORMATE IN THE PRESENCE OF AN ACID CATALYST AND AN ALCOHOL | BRISTOL-MYERS SQUIBB CO. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5688946-A | DIPEPTIDES FOR HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | HOFFMANN LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| US-5672599-A | DUAL ACTION ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND NEUTRAL ENDOPEPTIDASE INHIBITORS; TREATMENT OF CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5670699-A | Process for preparing amino acid esters useful as intermediates for compounds containing a fused bicyclic ring | BRISTOL-MYERS SQUIBB CO. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5627278-A | MULTISTAGE REACTION FORMED BY AMIDATION, COUPLING AND REDUCTION | BRISTOL-MYERS SQUIBB CO. (US) | 1997-05-06 | — | — | US | disclosed |
| US-5616775-A | ESTERIFYING A N-PROTECTED METHIONINE; OXIDIZING; REACTING WITH AN ACID ANHYDRIDE THEN AN ALKALI METAL HYDROXIDE | BRISTOL-MYERS SQUIBB CO. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5508272-A | SELECTIVE ACE INHIBITORS, HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0629627-A2 | Bicyclic carboxylic acids and their derivatives as nep and aca inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | SCN9A 3795/4885ITGB3 4288/4885ITGA2B 4447/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | SCN9A 3795/4885ITGB3 4288/4885ITGA2B 4447/4885 |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | NCOR2, NSD2, NCOR1 | SCN9A 4485/4885ITGB3 4726/4885ITGA2B 4386/4885 |
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | SCN9A 3327/4885ITGB3 3155/4885ITGA2B 3247/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | SCN9A 3327/4885ITGB3 3155/4885ITGA2B 3247/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | SCN9A 3935/4885ITGB3 2895/4885ITGA2B 3131/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | SCN9A 3795/4885ITGB3 4288/4885ITGA2B 4447/4885 |
| US-11952352-B2 | Ras inhibitors | KRAS, NRAS, HRAS | SCN9A 3327/4885ITGB3 3155/4885ITGA2B 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.